Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients.
about
Systemic treatments for metastatic cutaneous melanomaPhase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanomaTreatment of metastatic melanoma: an overviewOptimal management of metastatic melanoma: current strategies and future directionsMeta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant MelanomaChemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in miceAutophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy.Results of systemic treatment of cutaneous melanoma in inoperable stage III and IVPhase II assessment of talabostat and cisplatin in second-line stage IV melanoma.Expression of novel cancer/testis antigen TMEM31 increases during metastatic melanoma progression.Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysisHigh activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study.IL28B polymorphism cannot predict response to interferon alpha treatment in patients with melanoma.XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial cETM study of electroporation influence on cell morphology in human malignant melanoma and human primary gingival fibroblast cells.Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.Biomarkers as key contributors in treating malignant melanoma metastases.Systematic review of medical treatment in melanoma: current status and future prospects.Novel dendritic cell-based vaccination in late stage melanomaNew challenges in endpoints for drug development in advanced melanomaClinical and immunologic basis of interferon therapy in melanoma.Immunotherapy of cancer in 2012.Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma.Chemotherapy in the management of advanced cutaneous malignant melanoma.Update on use of aldesleukin for treatment of high-risk metastatic melanoma.Vaginal primary malignant melanoma: a rare and aggressive tumorRole of IL-2 in cancer immunotherapySystemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?Update on primary head and neck mucosal melanoma.Immunotherapy of distant metastatic disease.Current systemic therapy for metastatic melanoma.Novel therapeutics for the treatment of metastatic melanoma.Novel therapeutics for melanoma.Immunotherapy following regional chemotherapy treatment of advanced extremity melanomaChanging the clinical picture of challenging tumors: tales becoming reality?Primary Vaginal Melanoma, A Rare and Aggressive Entity. A Case Report and Review of the Literature.Malignant melanoma of the head and neck: a brief review of pathophysiology, current staging, and management.
P2860
Q24194804-788A6901-6D21-4CC1-A6FD-ADDF34220210Q24635643-F8DBC0B5-376A-4D2B-8DAA-4ED493CF9E39Q24642384-74CFC679-36D7-414F-8C61-607B600BFF1AQ26997338-CCD03F82-5C8C-4594-9C8C-C672258E80FCQ28074939-123795FB-EF65-4524-B794-60051413ECECQ28538913-8141AFD4-376B-44DC-8D26-43A9B5F466E7Q30402590-78001825-D796-4DF5-A71B-3794A3D7F8C6Q33408564-70C4D6AC-A8A2-47F4-82E7-8CDDE4F1FF10Q33488712-100A0291-934B-4922-803F-46D45CEFA1F9Q33597527-9E62323C-96E1-4C16-B997-ADC4991F93A6Q33667485-F59CDF4A-8D28-4492-9A2A-5A06E4593660Q33794086-A94E1E7B-26DB-4054-A982-5A773593A4AEQ34170003-921FC568-1D12-414E-A189-EA2C068F4E98Q34353577-ACDAEA42-7548-4D66-851A-3A574A9C8D0BQ34497983-AE167F24-A8AE-4861-93C6-2411DEDEF26AQ34521935-3AFE2AF5-FF3A-4A75-ACB5-1C16CBDB7E8BQ34600089-08A4213A-372F-49FF-926C-E950FE5B5BDFQ34660327-526D3335-82D3-470F-94B6-66C2F6CB4B36Q35034764-2ACD7E6F-DF77-4688-853F-53CEBCC311ADQ35550888-11014A51-B54A-4AF7-BA2E-EED3F98E7D3BQ35584299-35458656-2428-4DBF-8848-11E265E0B750Q35886439-B3F372FE-1608-4A7C-9D3F-14BD744221F7Q36175358-945AAD88-61A1-498C-BAA1-C35A73B4CA80Q36190624-B2FABD7E-074E-4CE9-8B43-42A3A7A06AFBQ36243536-15FA6ACB-66BC-497F-B9BD-CE4D2B3008BDQ36283747-B7A661AB-8D40-4A51-97A1-AEA44998EA90Q37007984-43E1EA72-1718-4CF8-BFC7-5BFBE7A20C96Q37031696-D00D3FF1-23C2-426A-BFBF-BA084A8EEB9AQ37077885-CC40CC59-1246-4575-B632-186948DD2D23Q37079072-3A4F8C04-1932-401F-B126-25A9F06502FDQ37099104-86F1293B-DB25-4F1D-8393-0C1DA04A0777Q37178922-9DF55453-20CA-4D34-8A0B-BC0B35A99A68Q37266668-FC2D6286-8DAF-4641-A8E5-5781E4F02BA0Q37483961-AE68E5CF-DA62-4C8A-A5EA-6267A6C9CB5DQ37486788-DC14C7FB-9490-4278-A28E-4FE3038ADA56Q37508041-2E26EB1E-8630-42D1-A810-3E47D8D59ED3Q37509709-349402C4-123D-4599-A224-6C433A15E125Q37575602-C7748A64-88AF-441A-B573-0628AEFCAD5BQ37705279-30F43616-2306-4B5F-A3FB-C604E8352A32Q37878331-0142A042-7602-4CB7-ABD2-15AAA8817CF7
P2860
Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients.
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Chemotherapy compared with bio ...... ials involving 2,621 patients.
@ast
Chemotherapy compared with bio ...... ials involving 2,621 patients.
@en
Chemotherapy compared with bio ...... ials involving 2,621 patients.
@nl
type
label
Chemotherapy compared with bio ...... ials involving 2,621 patients.
@ast
Chemotherapy compared with bio ...... ials involving 2,621 patients.
@en
Chemotherapy compared with bio ...... ials involving 2,621 patients.
@nl
prefLabel
Chemotherapy compared with bio ...... ials involving 2,621 patients.
@ast
Chemotherapy compared with bio ...... ials involving 2,621 patients.
@en
Chemotherapy compared with bio ...... ials involving 2,621 patients.
@nl
P921
P356
P1476
Chemotherapy compared with bio ...... ials involving 2,621 patients.
@en
P2093
Keith Wheatley
Natalie J Ives
P304
P356
10.1200/JCO.2007.12.0253
P407
P577
2007-12-01T00:00:00Z